SCHEMBL3623326

SCHEMBL3623326

N=C(N)NCCC[C@@H](C(=O)O)N(O)C(=O)OCc1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 6/20 0.51
SLC1A3 P43003 1/20 0.43
SLC1A1 P43005 1/20 0.43
HTT P42858 1/20 0.41
CCR6 P51684 1/20 0.40
PAX8 Q06710 1/20 0.40
SIRT2 Q8IXJ6 1/20 0.39
DPP8 Q6V1X1 1/20 0.39
DPP7 Q9UHL4 1/20 0.39
TGM2 P21980 1/20 0.38
MMP2 P08253 1/20 0.38
MMP9 P14780 1/20 0.38
LMNA P02545 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
ANPEP P15144 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2030161 0.90 FOLH1 (0.47) FOLH1SLC1A3SLC1A1HTTCCR6
SCHEMBL2030163 0.90 FOLH1 (0.47) FOLH1SLC1A3SLC1A1HTTCCR6
SCHEMBL30350537 0.88 FOLH1 (0.56) FOLH1SLC1A3SLC1A1HTTCCR6
SCHEMBL29266083 0.88 FOLH1 (0.46) FOLH1SLC1A3SLC1A1HTTCCR6
SCHEMBL7767627 0.84 FOLH1 (0.43) FOLH1SLC1A3SLC1A1HTTCCR6
SCHEMBL5981757 0.82 TPSAB1 (0.55) FOLH1SLC1A3SLC1A1HTTSIRT2
SCHEMBL7762891 0.81 FOLH1 (0.42) FOLH1SLC1A3SLC1A1HTTCCR6
SCHEMBL29517152 0.80 FOLH1 (0.42) FOLH1SLC1A3SLC1A1SIRT2DPP8
SCHEMBL7353231 0.79 HTT (0.41) FOLH1SLC1A3SLC1A1HTTCCR6
Arginine SCHEMBL2515487 0.78 SLC1A1 (0.47) FOLH1SLC1A3SLC1A1HTTCCR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2086531-A1 COMPOSITIONS AND TREATMENTS COMPRISING 5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITORS AND NITRIC OXIDE MODULATORS Amira Pharmaceuticals, Inc. (US) 2009-08-12 EP claimed
WO-2008067566-A1 COMPOSITIONS AND TREATMENTS COMPRISING 5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITORS AND NITRIC OXIDE MODULATORS AMIRA PHARMACEUTICALS, INC. (US) 2008-06-05 WO claimed
EP-2217589-A2 MODULATORS OF OCULAR OXIDATIVE STRESS ReVision Therapeutics, Inc. (US) 2010-08-18 EP disclosed
EP-2086531-A1 COMPOSITIONS AND TREATMENTS COMPRISING 5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITORS AND NITRIC OXIDE MODULATORS Amira Pharmaceuticals, Inc. (US) 2009-08-12 EP disclosed
WO-2009070693-A2 MODULATORS OF OCULAR OXIDATIVE STRESS SIRION THERAPEUTICS, INC (US) 2009-06-04 WO disclosed
EP-2037951-A2 METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY Sirion Therapeutics, Inc. (US) 2009-03-25 EP disclosed
EP-1807103-A4 MODULATORS OF RETINOL-RETINOL BINDING PROTEIN (RBP)-TRANSTHYRETIN (TTR) COMPLEX FORMATION SIRION THERAPEUTICS INC (US) 2009-02-11 EP disclosed
EP-1904043-A4 METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA SERUM RETINOL, SERUM RETINOL BINDING PROTEIN (RBP), AND/OR SERUM RETINOL-RBP MODULATION SIRION THERAPEUTICS INC (US) 2008-09-17 EP disclosed
WO-2008067566-A1 COMPOSITIONS AND TREATMENTS COMPRISING 5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITORS AND NITRIC OXIDE MODULATORS AMIRA PHARMACEUTICALS, INC. (US) 2008-06-05 WO disclosed
EP-1804788-A4 DETECTION AND ANALYSIS OF OPHTHALMICALLY-RELEVANT FLUORESCENT MOLECULES SIRION THERAPEUTICS INC (US) 2008-05-21 EP disclosed
EP-1827407-A4 METHODS, ASSAYS AND COMPOSITIONS FOR TREATING RETINOL-RELATED DISEASES SIRION THERAPEUTICS INC (US) 2008-05-21 EP disclosed
EP-1827407-A2 METHODS, ASSAYS AND COMPOSITIONS FOR TREATING RETINOL-RELATED DISEASES Sirion Therapeutics, Inc. (US) 2007-09-05 EP disclosed
EP-1807103-A2 MODULATORS OF RETINOL-RETINOL BINDING PROTEIN (RBP)-TRANSTHYRETIN (TTR) COMPLEX FORMATION Sirion Therapeutics, Inc. (US) 2007-07-18 EP disclosed
EP-1804788-A2 DETECTION AND ANALYSIS OF OPHTHALMICALLY-RELEVANT FLUORESCENT MOLECULES Sirion Therapeutics, Inc. (US) 2007-07-11 EP disclosed
EP-1768657-A1 METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS WITH RETINYL DERIVATES Sirion Therapeutics, Inc. (US) 2007-04-04 EP disclosed
WO-2007008821-A2 METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA SERUM RETINOL, SERUM RETINOL BINDING PROTEIN (RBP), AND/OR SERUM RETINOL-RBP MODULATION SIRION THERAPEUTICS, INC. (US) 2007-01-18 WO disclosed
WO-2006063128-A2 METHODS, ASSAYS AND COMPOSITIONS FOR TREATING RETINOL-RELATED DISEASES SIRION THERAPEUTICS, INC. (US) 2006-06-15 WO disclosed
WO-2006052860-A2 MODULATORS OF RETINOL-RETINOL BINDING PROTEIN (RBP)-TRANSTHYRETIN (TTR) COMPLEX FORMATION SIRION THERAPEUTICS, INC. (US) 2006-05-18 WO disclosed
WO-2006047475-A2 DETECTION AND ANALYSIS OF OPHTHALMICALLY-RELEVANT FLUORESCENT MOLECULES SYTERA, INC. (US) 2006-05-04 WO disclosed
WO-2006007314-A1 METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS WITH RETINYL DERIVATIVES SIRION THERAPEUTICS, INC. (US) 2006-01-19 WO disclosed